These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17718970)

  • 1. Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules.
    Temming K; Lacombe M; Moorlag HE; Asgeirsdottir SA; Orfi L; Kéri G; Poelstra K; Molema G; Kok RJ
    J Control Release; 2006 Nov; 116(2):e57. PubMed ID: 17718970
    [No Abstract]   [Full Text] [Related]  

  • 2. Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.
    Temming K; Lacombe M; Schaapveld RQ; Orfi L; Kéri G; Poelstra K; Molema G; Kok RJ
    ChemMedChem; 2006 Nov; 1(11):1200-3. PubMed ID: 16991175
    [No Abstract]   [Full Text] [Related]  

  • 3. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology.
    Temming K; Lacombe M; van der Hoeven P; Prakash J; Gonzalo T; Dijkers EC; Orfi L; Kéri G; Poelstra K; Molema G; Kok RJ
    Bioconjug Chem; 2006; 17(5):1246-55. PubMed ID: 16984135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.
    Temming K; Meyer DL; Zabinski R; Dijkers EC; Poelstra K; Molema G; Kok RJ
    Bioconjug Chem; 2006; 17(6):1385-94. PubMed ID: 17105215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
    Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
    AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia.
    Oda S; Nagahama R; Nakano K; Matoba T; Kubo M; Sunagawa K; Tominaga R; Egashira K
    J Vasc Surg; 2010 Aug; 52(2):412-20. PubMed ID: 20573471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
    Giles FJ; List AF; Carroll M; Cortes JE; Valickas J; Chen BL; Masson E; Jacques C; Laurent D; Albitar M; Feldman EJ; Roboz GJ
    Leuk Res; 2007 Jul; 31(7):891-7. PubMed ID: 17560285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
    Thomas AL; Morgan B; Horsfield MA; Higginson A; Kay A; Lee L; Masson E; Puccio-Pick M; Laurent D; Steward WP
    J Clin Oncol; 2005 Jun; 23(18):4162-71. PubMed ID: 15867205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
    Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J
    Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs.
    Dasa SSK; Suzuki R; Mugler E; Chen L; Jansson-Löfmark R; Michaëlsson E; Lindfors L; Klibanov AL; French BA; Kelly KA
    Nanomedicine; 2017 Nov; 13(8):2565-2574. PubMed ID: 28754465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis.
    Kim WJ; Yockman JW; Lee M; Jeong JH; Kim YH; Kim SW
    J Control Release; 2005 Aug; 106(1-2):224-34. PubMed ID: 15970348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.
    Tirand L; Frochot C; Vanderesse R; Thomas N; Trinquet E; Pinel S; Viriot ML; Guillemin F; Barberi-Heyob M
    J Control Release; 2006 Mar; 111(1-2):153-64. PubMed ID: 16423422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
    Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
    Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.